Novel approaches in the treatment of multiple myeloma.

Mehrdad Abedi, Gerald J. Elfenbein

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Despite all the new advances, treatment of multiple myeloma remains very challenging. Table 6 summarizes the outcomes of some of the commonly used treatments from different clinical trails. Treatment with conventional chemotherapy alone resulted in median survival from 18 to 30 months. Aggressive treatments like VBMCP (vincristine, bleomycin, melphalan, cyclophosphamide, predisone) although resulting in higher response rates, resulted in higher treatment-related mortality and did not have any effect on median and 5 year survival. High dose chemotherapy with stem cell support increased the median survival to around 60 months and resulted in durable complete responses in a significant number of the patients. Some of the newer and promising treatments for multiple myeloma are summarized in Table 7.

Original languageEnglish (US)
Pages (from-to)231-235
Number of pages5
JournalMedicine and health, Rhode Island
Issue number8
StatePublished - 2003
Externally publishedYes


Dive into the research topics of 'Novel approaches in the treatment of multiple myeloma.'. Together they form a unique fingerprint.

Cite this